On August 23, 2021, the Department of Defense (DoD) awarded a $600,000 contract to Qiagen to expand manufacturing capacity of enzymatic reagents and reagent kits used in COVID-19 molecular diagnostic tests.
The reagents Qiagen produces are used to detect SARS-CoV-2 in collected samples and require highly controlled, validated, and regulatory-compliant manufacturing processes and facilities. This industrial base expansion effort will allow Qiagen to increase its monthly production of reagent kits by 7,000 and enzymes by 5,100 milligrams in its Beverly, MA, facility by the end of February 2022 to support domestic laboratory testing for COVID-19.
